Published in Annu Rev Pharmacol Toxicol on January 01, 1998
Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J (2000) 1.74
The chemical defensome: environmental sensing and response genes in the Strongylocentrotus purpuratus genome. Dev Biol (2006) 1.54
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.50
Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam. Clin Pharmacol Ther (2011) 1.47
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol (1999) 1.33
Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol (2002) 1.33
Informatics confronts drug-drug interactions. Trends Pharmacol Sci (2013) 1.28
Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. Eur J Nucl Med Mol Imaging (2007) 1.25
Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol (2003) 1.21
Single-molecule fluorescence spectroscopy using phospholipid bilayer nanodiscs. Methods Enzymol (2010) 1.17
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs (2005) 1.09
Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials. Br J Pharmacol (2013) 1.09
Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica (2010) 1.06
Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther (2012) 1.04
3D hepatic cultures simultaneously maintain primary hepatocyte and liver sinusoidal endothelial cell phenotypes. PLoS One (2010) 1.03
Aging and the environment: a research framework. Environ Health Perspect (2005) 1.03
Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. Pharmacol Ther (2012) 1.01
Allosteric effects on substrate dissociation from cytochrome P450 3A4 in nanodiscs observed by ensemble and single-molecule fluorescence spectroscopy. J Am Chem Soc (2008) 1.00
CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol (2008) 0.99
The design of in vitro liver sinusoid mimics using chitosan-hyaluronic acid polyelectrolyte multilayers. Tissue Eng Part A (2010) 0.97
Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol (2007) 0.97
Phylogenetic analysis of the cytochrome P450 3 (CYP3) gene family. J Mol Evol (2003) 0.97
Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450. Proc Natl Acad Sci U S A (2011) 0.95
The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol (2003) 0.95
CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur J Clin Pharmacol (2009) 0.95
Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. Br J Clin Pharmacol (1999) 0.94
Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics (2009) 0.93
Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol (2004) 0.92
A comparative study of genome-wide transcriptional profiles of primary hepatocytes in collagen sandwich and monolayer cultures. Tissue Eng Part C Methods (2010) 0.91
Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol (2004) 0.91
Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.90
Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers. Eur J Clin Pharmacol (2006) 0.90
A novel type of allosteric regulation: functional cooperativity in monomeric proteins. Arch Biochem Biophys (2012) 0.89
Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs (2004) 0.89
The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use. Am J Obstet Gynecol (2012) 0.88
Effect of danshen extract on the activity of CYP3A4 in healthy volunteers. Br J Clin Pharmacol (2010) 0.87
The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol (2002) 0.87
Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin Pharmacol Toxicol (2012) 0.86
Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol (2006) 0.85
The effect of age on the discriminative stimulus effects of ethanol and its GABA(A) receptor mediation in cynomolgus monkeys. Psychopharmacology (Berl) (2011) 0.84
Integrated transcriptional and proteomic analysis with in vitro biochemical assay reveal the important role of CYP3A46 in T-2 toxin hydroxylation in porcine primary hepatocytes. Mol Cell Proteomics (2011) 0.84
Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. J Pharmacol Exp Ther (2013) 0.84
Update information on drug metabolism systems--2009, part I. Curr Drug Metab (2010) 0.83
Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling. Br J Clin Pharmacol (2013) 0.83
Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol (2010) 0.83
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy. J Pers Med (2012) 0.83
Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol (2003) 0.83
Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. Br J Cancer (2007) 0.83
Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. Eur J Clin Pharmacol (2012) 0.82
Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib. Drug Metab Dispos (2011) 0.82
Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions. Drug Metab Dispos (2013) 0.82
A novel framework for predicting in vivo toxicities from in vitro data using optimal methods for dense and sparse matrix reordering and logistic regression. Toxicol Sci (2010) 0.82
Cysteine 98 in CYP3A4 contributes to conformational integrity required for P450 interaction with CYP reductase. Arch Biochem Biophys (2006) 0.81
Enzymatic detoxication, conformational selection, and the role of molten globule active sites. J Biol Chem (2013) 0.81
Drug-Drug Interactions Potential of Icariin and Its Intestinal Metabolites via Inhibition of Intestinal UDP-Glucuronosyltransferases. Evid Based Complement Alternat Med (2012) 0.80
Characterization of T-5 N-oxide formation as the first highly selective measure of CYP3A5 activity. Drug Metab Dispos (2013) 0.80
Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants. Clin Pharmacol Drug Dev (2014) 0.80
Modeling human liver biology using stem cell-derived hepatocytes. Int J Mol Sci (2013) 0.80
Intestinal cytochromes P450 regulating the intestinal microbiota and its probiotic profile. Microb Ecol Health Dis (2012) 0.80
Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects. Acta Pharmacol Sin (2009) 0.80
Role of reactive metabolites in the circulation in extrahepatic toxicity. Expert Opin Drug Metab Toxicol (2012) 0.79
A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system. Drug Metab Dispos (2006) 0.79
Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity. CPT Pharmacometrics Syst Pharmacol (2015) 0.79
Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition. J Clin Pharmacol (2006) 0.78
Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions. Chem Res Toxicol (2016) 0.78
Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. Br J Clin Pharmacol (2005) 0.78
Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol (2001) 0.78
Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions. Drug Metab Dispos (2013) 0.78
In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol (2000) 0.78
Hydroxylation of 20-hydroxyvitamin D3 by human CYP3A4. J Steroid Biochem Mol Biol (2016) 0.77
Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest (2007) 0.77
Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. Br J Clin Pharmacol (2005) 0.77
Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients. Br J Clin Pharmacol (2003) 0.77
Marine invertebrate xenobiotic-activated nuclear receptors: their application as sensor elements in high-throughput bioassays for marine bioactive compounds. Mar Drugs (2014) 0.77
Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects. Eur J Clin Pharmacol (2005) 0.77
Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases. Biomark Insights (2007) 0.77
Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. PLoS One (2015) 0.77
Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions. J Cancer (2016) 0.77
Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities. Drug Metab Pharmacokinet (2012) 0.77
Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases. Sci Rep (2015) 0.76
Interactions of grapefruit juice and cardiovascular medications: A potential risk of toxicity. Exp Clin Cardiol (2003) 0.76
ABCB1 transporter and Toll-like receptor 4 in trabecular meshwork cells. Mol Vis (2015) 0.76
Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord (2016) 0.76
Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome. Pediatr Nephrol (2012) 0.76
Correlations of CYP2C9*3/CYP2D6*10/CYP3A5*3 gene polymorphisms with efficacy of etanercept treatment for patients with ankylosing spondylitis: A case-control study. Medicine (Baltimore) (2017) 0.75
Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. Malar J (2014) 0.75
Alteration in the expression of cytochrome P450s (CYP1A1, CYP2E1, and CYP3A11) in the liver of mouse induced by microcystin-LR. Toxins (Basel) (2015) 0.75
Saint John's wort, an herbal inducer of the cytochrome P4503A4 isoform, may alleviate symptoms of Willis-Ekbom's disease. Clinics (Sao Paulo) (2013) 0.75
The Effect of Vinpocetine on Human Cytochrome P450 Isoenzymes by Using a Cocktail Method. Evid Based Complement Alternat Med (2016) 0.75
A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate. Eur J Clin Pharmacol (2003) 0.75
Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4. Proc Natl Acad Sci U S A (2016) 0.75
Pharmacokinetic drug interactions in liver disease: An update. World J Gastroenterol (2016) 0.75
Evaluation of amphotericin B and chloramphenicol as alternative drugs for treatment of chytridiomycosis and their impacts on innate skin defenses. Appl Environ Microbiol (2014) 0.75
Effect of CYP3A4(∗)1G and CYP3A5(∗)3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects. Front Pharmacol (2017) 0.75
Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping. Ther Drug Monit (2015) 0.75
Polymorphisms and phenotypic analysis of cytochrome P450 3A4 in the Uygur population in northwest China. Int J Clin Exp Pathol (2015) 0.75
Serum alanine transaminase total bilirubin concentrations predict CYP3A activity as measured by midazolam and 1'-hydroxylation. Med Sci Monit (2015) 0.75
The roles of carboxylesterase and CYP isozymes on the in vitro metabolism of T-2 toxin. Mil Med Res (2015) 0.75
Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism. PLoS One (2016) 0.75
Gomisin A is a Novel Isoform-Specific Probe for the Selective Sensing of Human Cytochrome P450 3A4 in Liver Microsomes and Living Cells. AAPS J (2015) 0.75
Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther (1975) 7.96
The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest (1975) 4.65
Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med (1981) 3.98
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol (1994) 3.05
Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther (2001) 2.79
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther (1985) 2.69
Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med (1989) 2.29
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (1999) 2.24
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther (1984) 2.19
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos (1999) 2.02
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation (1999) 2.01
Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem (1985) 1.97
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos (2000) 1.87
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther (1996) 1.85
Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. J Clin Invest (1974) 1.74
Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med (1976) 1.68
Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther (1979) 1.62
Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol (1978) 1.60
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol (2001) 1.59
Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther (1979) 1.55
Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium). Gastroenterology (1978) 1.48
Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med (1982) 1.43
CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther (2000) 1.42
Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther (1978) 1.39
Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther (1985) 1.38
Biological determinants of propranolol disposition in man. Clin Pharmacol Ther (1978) 1.35
Altered hepatic blood flow and drug disposition. Clin Pharmacokinet (1976) 1.34
Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther (1978) 1.33
Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics (1999) 1.33
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther (1999) 1.32
Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry (1984) 1.29
The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokinet (1979) 1.28
Clearance approaches in pharmacology. Pharmacol Rev (1987) 1.27
Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J Pharmacol Exp Ther (1987) 1.25
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation (1987) 1.22
Normal metabolism of morphine in cirrhosis. Gastroenterology (1981) 1.22
The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther (1974) 1.22
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther (1998) 1.21
Erythrocyte uptake and plasma binding of diphenylhydantoin. Clin Pharmacol Ther (1974) 1.21
Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives. Clin Pharmacol Ther (1979) 1.16
Drug disposition and liver disease. Drug Metab Rev (1975) 1.14
P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res (1999) 1.14
Induction of propranolol metabolism by rifampicin. Br J Clin Pharmacol (1983) 1.13
Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol (1990) 1.13
Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med (1977) 1.13
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics (2001) 1.12
Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res (1987) 1.12
Effects of liver disease on drug disposition in man. Biochem Pharmacol (1976) 1.11
Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res (1984) 1.11
The oral yeast flora of 10-year-old schoolchildren. Sabouraudia (1983) 1.10
The reduction of lidocaine clearance by dl-propranolol: an example of hemodynamic drug interaction. J Pharmacol Exp Ther (1973) 1.10
Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther (1978) 1.10
Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther (1993) 1.09
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics (1998) 1.09
The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther (1990) 1.08
Effect of hypotension on liver blood flow and lidocaine disposition. N Engl J Med (1982) 1.08
Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital. Clin Pharmacol Ther (1986) 1.08
Suppression of ventricular ectopic depolarizations by tocainide. Circulation (1977) 1.06
Pharmacokinetics of drug disposition: hemodynamic considerations. Annu Rev Pharmacol (1975) 1.06
Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output. J Pharmacol Exp Ther (1968) 1.05
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther (1989) 1.05
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther (1999) 1.05
Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther (1999) 1.04
Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther (1994) 1.03
Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarkers Prev (1999) 1.03
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses (2000) 1.02
Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther (1984) 1.02
Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther (1998) 1.01
Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. Mol Pharmacol (1992) 1.01
Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther (1977) 1.01
Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum (1986) 0.99
Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther (1987) 0.98
Bupivacaine levels in plasma and cerebrospinal fluid following peridural administration. Anesthesiology (1970) 0.97
Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin. Clin Pharmacol Ther (1990) 0.96
Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther (1988) 0.96
Plasma binding of benzodiazepines in humans. J Pharm Sci (1979) 0.95
Interaction of quinidine with anticonvulsant drugs. N Engl J Med (1976) 0.95
Perfusion-limited of plasma drug binding on hepatic drug extraction. Life Sci (1976) 0.94
Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. Br J Clin Pharmacol (1999) 0.94
Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther (1990) 0.94
Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. J Clin Invest (1984) 0.93
Drug metabolites in renal failure: pharmacokinetic and clinical implications. Clin Pharmacokinet (1982) 0.93
Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos (1987) 0.93
Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade. Clin Pharmacol Ther (1984) 0.93
Abnormal regulation of plasma pyridoxal 5'-phosphate in patients with liver disease. Gastroenterology (1976) 0.92
Meperidine disposition in man: influence of urinary pH and route of administration. Clin Pharmacol Ther (1981) 0.92
Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine. Br J Clin Pharmacol (1989) 0.92
Effect of heparin administration on plasma binding of benzodiazepines. Br J Clin Pharmacol (1980) 0.91
In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther (1996) 0.90
Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. J Pharmacol Exp Ther (1988) 0.90
Effects of alteration of hepatic microsomal enzyme activity on liver blood flow in the rat. Biochem Pharmacol (1976) 0.90
Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther (1986) 0.90
Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol (1980) 0.90
S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families. Clin Pharmacol Ther (1987) 0.89
Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in man. Clin Pharmacol Ther (1976) 0.89
The influence of indomethacin on the pharmacokinetics, diuretic response and hemodynamics of furosemide in the dog. J Pharmacol Exp Ther (1978) 0.88
Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr (1984) 0.88
Absorption, metabolism, and excretion of the ephedrines in man. II. Pharmacokinetics. J Pharm Sci (1968) 0.88